Division of Cardiovascular Medicine, University of California, San Francisco, San Francisco, CA, USA.
Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
J Interv Card Electrophysiol. 2021 Jun;61(1):145-154. doi: 10.1007/s10840-020-00775-1. Epub 2020 Jun 6.
Prior studies reporting efficacy of radiofrequency catheter ablation for complex ventricular ectopy in mitral valve prolapse (MVP) are limited by selective inclusion of bileaflet MVP, papillary muscle only ablation, or short-term follow-up. We sought to evaluate the long-term incidence of hemodynamically significant ventricular tachycardia (VT) or fibrillation (VF) in patients with MVP after initial ablation.
We studied consecutive patients with MVP undergoing ablation for complex ventricular ectopy between 2013 and 2017 at our institution. Of 580 patients with MVP, we included 15 (2.6%, 10 women; mean age 50 ± 14 years, 53% bileaflet) with complex ventricular ectopy treated with initial ablation.
Over a median follow-up of 3406 (1875-6551) days or 9 years, 5 of 15 (33%) patients developed hemodynamically significant VT/VF after their initial ablation and underwent placement of an implantable cardioverter defibrillator (ICD). Three of 5 also underwent repeat ablations. Sustained VT was inducible prior to index ablation in all 5 who developed VT/VF, compared to none of the 10 patients who did not develop VT/VF after index ablation (p = 0.002). Complex ventricular ectopy at index ablation was multifocal in all 5 patients who underwent repeat intervention versus 4 of 10 patients (40%) who did not (p = 0.04). All 3 patients with subsequent VT/VF who underwent repeat ablation had a new clinically dominant focus of ventricular arrhythmia and 3 of the patients with ICD had appropriate VT/VF therapies.
In the long term, a subset of MVP patients treated with ablation for ventricular arrhythmias, all with multifocal ectopy on initial EP study, develop hemodynamically significant VT/VF. Our findings suggest the progressive nature of ventricular arrhythmias in patients with MVP and multifocal ectopy.
先前报道射频导管消融治疗二尖瓣脱垂(MVP)复杂室性心律失常疗效的研究受到选择性纳入双叶 MVP、乳头肌消融或短期随访的限制。我们旨在评估 MVP 患者初始消融后发生血流动力学显著室性心动过速(VT)或颤动(VF)的长期发生率。
我们研究了 2013 年至 2017 年期间在我院因复杂室性心律失常行消融术的连续 MVP 患者。在 580 例 MVP 患者中,我们纳入了 15 例(2.6%,10 例女性;平均年龄 50±14 岁,53%为双叶)行初始消融术治疗的复杂室性心律失常患者。
在中位随访 3406(1875-6551)天或 9 年期间,15 例初始消融患者中有 5 例(33%)发生血流动力学显著 VT/VF,并植入植入式心脏复律除颤器(ICD)。5 例中有 3 例还接受了重复消融。与未发生消融后 VT/VF 的 10 例患者相比,所有 5 例发生 VT/VF 的患者在索引消融前均能诱发出持续性 VT(p=0.002)。在所有 5 例重复干预的患者中,初始消融时复杂室性心律失常呈多灶性,而在未发生 VT/VF 的 10 例患者中,4 例(40%)为多灶性(p=0.04)。在随后发生 VT/VF 并接受重复消融的 3 例患者中,均有新的优势型致心律失常性室性心律失常灶,3 例 ICD 患者发生了恰当的 VT/VF 治疗。
在长期随访中,接受消融术治疗室性心律失常的 MVP 患者中有一部分患者(均在最初的 EP 研究中存在多灶性室性异位)发生了血流动力学显著的 VT/VF。我们的研究结果表明 MVP 患者存在多灶性室性异位的情况下,室性心律失常具有进行性。